Skip Nav Destination
You do not currently have access to this content.
A More Selective FGFR Inhibitor for Bladder Cancer
November 6, 2024
A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer. Partial responses have been seen in an ongoing phase I trial, and the drug is much better tolerated than erdafitinib, a pan–FGFR inhibitor and an approved second-line therapeutic option.
DOI:https://doi.org/10.1158/2159-8290.CD-NW2024-0082
Publisher:American Association for Cancer Research
Article Type:
News
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Advertisement